Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.
Nikolaos ZacharakisLutfi M HuqSamantha J SeitterSanghyun P KimJared J GartnerSivasish SindiriVictoria K HillYong F LiBiman C PariaSatyajit RayBillel GasmiChyi-Chia LeeTodd D PrickettMaria R ParkhurstPaul F RobbinsMichelle M LanghanThomas E SheltonAnup Y ParikhShoshana T LeviJonathan M HernandezChuong D HoangRichard M SherryJames C YangSteven A FeldmanStephanie L GoffSteven A RosenbergPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Most patients with breast cancer generated a natural immune response targeting the expressed products of their cancer mutations. Adoptive transfer of TIL is a highly personalized experimental option for patients with mBrCa shown to be capable of mediating objective responses in this pilot trial and deserves further study.
Keyphrases
- phase ii
- clinical trial
- open label
- immune response
- cell therapy
- study protocol
- papillary thyroid
- phase iii
- double blind
- placebo controlled
- bone marrow
- peripheral blood
- randomized controlled trial
- squamous cell
- stem cells
- cancer therapy
- childhood cancer
- lymph node metastasis
- mesenchymal stem cells
- platelet rich plasma
- young adults